What we do Lincoln Pharmaceuticals Ltd manufactures and trades pharmaceutical formulations focusing on anti-infectives, respiratory, gynecology, cardio, CNS, anti-diabetic, and anti-malarial products. |
Founded in 1,979 |
Market share Well-established player in domestic and export pharmaceutical markets with growing presence in cephalosporin and parenteral segments. |
Problem solved Addresses critical healthcare needs by providing essential medicines for infectious, chronic, and specialty diseases. |
Top clients or who we serve Serves hospitals, pharmacies, healthcare providers, and export markets (B2B and B2C). |
Key management Mahendra G. Patel (Managing Director), Hashmukh I. Patel (Whole-Time Director) |
Our journey and innovations Founded as partnership in 1979, became a public company in 1995, expanded manufacturing including parenterals and Cephalosporin production. |
Where we operate Major presence in India with export operations globally. |
Top products or what we offer Pharmaceutical formulations including ProlinSpray (progesterone therapy) and Cephalosporin injections from Mehsana plant. |
Top brands ProlinSpray (next-gen progesterone therapy), various anti-infective and respiratory brands; key revenue drivers with pan-India and export reach. |
Raw materials needed Active pharmaceutical ingredients (APIs), chemicals for formulation production. |
Raw materials supplier Multiple suppliers including loan-license manufacturers for specific products. |
Recurring vs cyclical contribution Primarily recurring revenues driven by pharmaceutical product sales with steady demand. |
Our industry position Recognized mid-tier pharmaceutical manufacturer with diversified product portfolio and export capabilities. |
Financial highlights FY25 revenue ₹623.23 crores, net profit ₹82.35 crores, with 7.35% revenue growth year-over-year. |
Geographical revenue split Domestic revenue ₹236.01 crores, Export revenue ₹387.22 crores accounting for majority of sales. |
Order book - |
Whats driving growth Capacity expansion in parenteral and Cephalosporin segments, export market growth, and new product launches. |
Our future plans Enhance manufacturing capabilities and launch additional specialty formulations to increase market share. |
Our green promise - |
Our people and values Committed to inclusive workplace, employee engagement, and ethical governance practices. |
Key challenges ahead Managing regulatory compliance, market competition, raw material cost volatility, and export market fluctuations. |
Interesting facts Launched ProlinSpray, an innovative next-generation progesterone therapy, expanding its specialty portfolio. |
Risks and strategy Mitigates risks via robust internal controls, compliance policies, and continual product quality improvements. |
